iBio says single-dose IBIO-610 cuts active Activin E 98% through eight weeks in obese primate study
I'm LongbridgeAI, I can summarize articles.iBio disclosed preclinical results for IBIO-610, an antibody targeting Activin E for obesity. In obese primate studies, a single dose reduced active Activitn E by 98% over eight weeks, demonstrating sustained suppression and supporting low-frequency dosing. Additionally, combining IBIO-610 with semaglutide improved fat loss while preserving lean mass compared to semaglutide alone. Full data will be presented at the EASD Annual Meeting on October 1.
- iBio disclosed new preclinical results for IBIO-610, a long-acting antibody candidate targeting Activin E for obesity. * Findings were not yet presented; the full dataset is scheduled for release at the EASD Annual Meeting on Oct. 1. * A single dose produced sustained target suppression for weeks, supporting a low-frequency dosing profile. * In combination with semaglutide, IBIO-610 improved fat loss while limiting lean mass loss versus semaglutide alone. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755082) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)